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ABSTRACT 
Behaviours which are associated with the preservation of health include: non smoking, regular 
exercise, a low body weight, a healthy diet and a low alcohol intake. Together, as a healthy lifestyle, 
these have been shown to be associated with marked protection against a wide range of diseases: 
diabetes, vascular disease, cancer and dementia. On the other hand, the protection associated with 
statins and aspirin, the two most commonly used preventive drugs, is limited to vascular disease 
and, probably for aspirin, cancer. 
These are not alternative prophylactics and any two, or all three – a healthy lifestyle, a statin and 
aspirin - can reasonably be taken together.   
Only a small proportion of the members of the community follow a healthy lifestyle. Yet a small 
increase in the uptake of a the healthy behaviours throughout the community can be shown to 
have relatively large effects on the incidence of disease.   
There is therefore an urgent need for health promotion activities across the whole community to 
be greatly increased and for new challenging and encouraging strategies to be devised and tested. 
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Introduction 
‘The unexamined life is not worth living’  Socrates 
Introduction: Clinical practice focuses on the individual rather than the community and yet, as 
Geoffrey Rose pointed out 40 years ago,1 the bulk of disease and disablement comes not from the 
sub-group of high-risk subjects but from the general community, simply because the community is 
numerous and the risk-factors for most diseases are multiple and are distributed throughout the 
whole population.   
WHO defines the ultimate aim of medical practice to be ‘a state of complete physical, mental and 
social wellbeing and not merely the absence of disease’2 and so a major goal of health authorities 
and healthcare workers, should include the raising of the level of wellbeing throughout the 
community, and not just the reduction of the suffering and misery of patients with disease. 
In what follows we compare the reductions in the incidence of a number of important chronic 
diseases associated with the following of a healthy lifestyle and the reductions associated with the 
taking of two commonly used prophylactic drugs: statins and aspirin. We also consider the side 
effects of the three preventive measures. 
A healthy lifestyle: The Caerphilly Collaborative Cohort Study was a 35-year prospective study, set 
up in 1979 and based on a representative population sample of 2,500 men aged 45-59 years.3 
Caerphilly in Wales UK was chosen for the study because the social class distribution of the 
population in the town was closely similar to that of the whole of England & Wales. Electoral rolls 
and Primary Care practice lists were used as a sampling frame and 89% of the eligible subjects within 
the defined area gave signed agreement to long-term involvement in the research.   
Special afternoon and evening clinics were held and following attendance each man was asked to 
return the next morning, before breakfast, for a fasting blood sample to be taken. Every five years 
the men were seen again: re-questioned, re-examined and further fasting blood samples taken. 
Around 95% of the survivors were questioned and examined at each five-year examination. 
Data were collected every five years on five behaviours which have repeatedly been shown to be 
associated with reductions in disease: non-smoking; regular physical activity (at least ½ an hour five 
days each week); a low body weight (BMI 18.5-25); a healthy diet (‘five a day’ fruit and vegetables) 
and an intake of alcohol within the current guidelines. Two subgroups of men were identified: 111 
men (5% of the cohort) who consistently reported that they were following either four or five of the 
healthy behaviours and on these criteria were judged to be living a ‘healthy’ lifestyle, and 881 men 
(39% of the cohort) who said they followed either none, or only one of the behaviours and were 
judged to be living an ‘unhealthy’ lifestyle.  
Evidence on incident disease was collected repeatedly from primary care and hospital records and 
was evaluated against accepted clinical criteria as described elsewhere.4 Within the total cohort 214 
men developed diabetes within the 35 years of follow-up, 753 experienced a myocardial infarct or a 
stroke, and 299 men were diagnosed with cancer. Dementia was diagnosed in a clinical examination 
by a geriatrician and a neurologist in 121 men following detailed and repeated testing of cognitive 
function.4   
The trends in disease incidence and the number of healthy behaviours followed were significantly 
associated with incident diabetes, vascular disease, and dementia (see the Table). For incident cancer 
the reduction (32%) was only suggestive (P=0.06). However, access to BIOBANK UK gave opportunity 
for the conduct of a closely similar analysis and the association between a healthy lifestyle in 350,000 
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subjects with 14,500 new cancers. This confirmed a reduction associated with a healthy lifestyle of 
32% in incident cancer, during a five-year follow-up (HR 0.68, 95% confidence intervals 0.63, 0.74; 
P<0.0001).5 
A healthy lifestyle which has been defined as above appears not to be associated with any 
undesirable side effect. During the conduct of the Caerphilly Study estimates of a number of aspects 
of ‘wellbeing’ were made when the men in the study were aged 75-89 years. Thus 89% of those who 
had followed a healthy lifestyle (four or five of the behaviours) claimed that they were ‘in good 
health’ as assessed by the General Health Questionnaire6 compared with 53% of the subjects who 
had been following an unhealthy behaviour (none or a single behaviour) (P<0.005). A ‘satisfaction 
with life’ score7 was 28 in those following a healthy lifestyle and 26 in those following an unhealthy 
lifestyle (P<0.06), and ‘positive attitudes’8 were shown by a greater proportion (P<0.001) of those 
who were following a healthy lifestyle.    
Statins: Over 40% of adult subjects in the USA take a statin,9 and it is estimated that ‘one third of the 
5.5 million people over age 75 in the UK take statins’.10 In fact, the National Institute for Health and 
Care Excellence (NICE) has issued guidelines within which almost all men aged over 60 and  women 
over 75 in England qualify for statin use.11  
Efficacy of statins against vascular disease has been shown in numerous randomised trials and 
although their use in healthy subjects is somewhat controversial, the marked reduction shown in the 
table has been taken from a randomised trial based on 17,802 ‘apparently healthy men and 
women’.12 
Statins however are a frequent cause of muscle cramps, estimated to affect one in every 10 persons 
taking the drug,  and rarely muscle necrosis,13 and these side effects lead to poor long term 
compliance with taking the drug.14 More importantly, there is evidence consistent with an increase 
in diabetes in subjects taking the drug, estimated to amount to between about one new case in every 
5013 and one in every 223 patients taking a statin.15    
Aspirin: Almost 20% of adults in the USA take aspirin daily or on alternate days,9 and a survey in 
Wales found that about 30% of men and 20% of women over age 50 take daily aspirin, with a 
significant bias in favour of the more privileged social classes.16   
Aspirin was first shown in 1974 to reduce vascular mortality17 and a meta-analysis of six primary 
prevention trials with a total of 95,000 participants confirmed a significant reduction in serious 
vascular disease events (relative risk 0.89; 95% CI 0.85-0.93; P < 0.001).18 More recently a number of 
long-term follow-up studies of vascular disease prevention have given evidence of a reduction in 
cancer incidence and cancer mortality associated with having been randomised to aspirin,19 and most 
recently, evidence consistent with a significant increase in the survival of patients with cancer and a 
reduction in metastatic spread associated with aspirin has been reported.20 
Low-dose aspirin taking increases the background risk of a gastrointestinal bleed by about 50%, 
equivalent to a bleed in an additional one or two persons in every 1,000 during the first few years of 
taking the drug.19,21 The drug is also rarely associated with intra-cerebral bleeding, equivalent to 
about one or two in every 10,000 subjects per year,22 though identification and treatment of 
hypertension appears to prevent a cerebral bleed.23  
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Discussion: Evidence on the benefits of lifestyles was selected from the Caerphilly Study in Wales 
because it had been conducted over a longer period of time than any other similar study, and it was 
the first to include dementia as an outcome.4 Due to limited funding at base-line it had been based 
on men alone, and questions therefore arise as to the acceptability of extrapolations of the results 
to the general community. Elsewhere we examine this point and we show that the results from 
studies based on men and women in communities within the USA,24-26 within Europe27 and in 
England28 are reasonably similar to those we report for men in Caerphilly.4   
There appear to be no interactions between the three prophylactics – a healthy lifestyle; statins and 
low-dose aspirin - and they should not therefore be considered as competitive alternatives. There is 
no reason therefore why two, or perhaps all three of the preventives should not be taken for 
protection against vascular disease events. At the same time, it seems unfortunate that there is a 
marked year-on-year decline in the prescribing of aspirin in the UK in favour of newer and more 
expensive antiplatelet and antithrombotic agents,29 for none of which is there evidence suggestive 
of a reduction in cancer. 
Although the three strategies are not alternatives for heart disease protection, the overall evaluation 
of the value of each should take account of background changes in the relative risks and the relative 
importance of the diseases relevant to their use. Thus: ischaemic heart disease has decreased in the 
UK by about 45% and ischaemic stroke by about 20% over the past 25 years.30  In contrast, the 
incidence of diabetes has more than doubled in the UK within the last twenty years,31 and overweight 
alone appears to explain about 70% of this increase.4  A major, and growing concern is dementia, and 
it has been estimated that the number of people with dementia in the UK is likely to double every 
five years.32 While the table shows that all three prophylactics are associated with a reduction in 
vascular disease outcomes, yet out of the three only a healthy lifestyle is associated with reductions 
in diabetes and in dementia.  
Elwood PC, Gallacher AM, Duthie GG et al. Aspirin, salicylates and cancer.  Lancet 2009;373:1301-9Rose1 and others 
have pointed out that a small shift in a distribution of a factor predictive of a disease can have a large 
effect on the population incidence of 
the disease, and the effect can be 
marked at an extreme of the 
distribution. Thus: suppose that at 
base-line in 1979 when the Caerphilly 
cohort was set up, every subject in the 
cohort had been urged to take up and 
follow just one additional healthy 
behaviour – either stop smoking or 
achieve an acceptable BMI or take 
regular exercise or chose a more 
healthy diet or reduce alcohol intake 
to within the accepted guidelines, and 
suppose that only half of the subjects 
had done so (other than the <1% of subjects who had consistently followed all five behaviours), then 
over the next 35 years there would have been within the cohort, about 12% less diabetes; about 6% 
fewer strokes and heart attacks, about 9% fewer patients with cancer, 13% fewer cases of dementia 
and an overall increase in wellbeing.4 
It has to be accepted however that while the estimates of reduction shown in the table for the two 
drugs have been obtained from randomised controlled trials,12,18 the results for the effects of a 
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healthy lifestyle were observational and it has not been possible to adjust the estimates for 
confounding by factors other than age and social class, and for dementia an adjustment was also 
made for pre-morbid cognitive ability.4 ‘Lifestyle’ is a complex and composite way of life determined 
in part by attitude to life and to relationships which go beyond the five behaviours on which we have 
data. Nevertheless, although the statistical reductions in disease which are attributed in this report 
to the five healthy behaviours may be somewhat over-estimated, clinical and other studies give 
convincing evidence of strong causal relationships between each of the behaviours and disease 
incidence. 
Finally, in the most recent data from the annual National Survey of Wales in 201833 the application 
of the same criteria of healthy lifestyles as were used in the Caerphilly study4 to the raw data on 
behaviours collected from 11,000 subjects in 2018 indicate that only 4.8% of the adult Welsh 
population follow a healthy lifestyle (four or five of the healthy behaviours) while 45% follow none, 
or only a single healthy behaviour. 
Conclusion: Now, with an ageing population in the UK; with the sustainability of the National Health 
Service and other health and social provisions being questioned;28 and with the huge neglect of 
healthy living, it would seem to be prudent for the current health promotion activities across the 
whole community to be substantially increased; for the awareness of the benefits of a healthy 
lifestyle to health and to wellbeing to be raised throughout the population, and for new challenging 
and encouraging health-promotion strategies to be devised and tested. 
 
 
Table: Estimates of reductions in incident disease associated with a healthy 
lifestyle in a large long-term observational cohort study; and reductions 
attributable to daily statin taking and daily aspirin taking in selected primary 
randomised controlled trials. 
 
Prophylactic 
strategy 
Reductions in disease incidence  
Diabetes Vascular disease Cancer Dementia 
Healthy living 72% 
reductiona 
(P<0.0005) 
62% 
reductiona 
(P<0.0005) 
32% 
reductiona,b 
(P<0.0001) 
65% 
reductiona 
(P<0.0005) 
Statins  
increasec 
 
44% 
reductiond 
(P<0.00001 
No 
change 
No  
change 
Aspirin No 
change 
11% 
reductione 
(P<0.001) 
29% 
reductionf 
(P<0.003) 
No 
change 
 
a. Reductions in the Caerphilly Cohort Study. Adjustments have been made for age and social class, and, for 
dementia adjustments were also made for premorbid cognitive function (ref. 4) 
b. Reduction in 14,500 cancers in 350,000 subjects in BIOBANK UK (ref.5) 
c. See text and refs 13-15. 
d. The reduction in ‘17,802 apparently healthy men and women’ (ref. 12). 
e. The reduction in primary prevention in a meta-analysis of 17 randomised trials (ref. 18)  
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f. The reduction in incident cancer in 32,996 subjects in six primary trials (ref 19). 
 
References 
1. Rose G. Strategy of prevention: lessons from cardiovascular disease. Br Med J (Clin Res Ed) 1981; 282: 1847-51. 
2. World Health Organization. BMJ 2011;343:d4163 
3. The Caerphilly and Speedwell Collaborative Group. Caerphilly and Speedwell collaborative heart disease studies. 
J Epidemiol Community Health 1984; 38(3): 259-62. 
4. Elwood P, Galante J, Pickering J, et al. Healthy lifestyles reduce the incidence of chronic diseases and dementia: 
evidence from the Caerphilly cohort study. PLoS One 2013; 8: e81877. 
5. Elwood PC, Whitmarsh A, Gallacher J, et al. Healthy living and cancer: evidence from UK Biobank. 
Ecancermedicalscience 2018; 12: 792-. 
6. Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. Psychol Med 1979; 9: 139-45. 
7. Diener E, Emmons RA, Larsen RJ, Griffin S. The Satisfaction with Life Scale. J Pers Assess 1985; 49: 71-5. 
8. Kuppens P, Realo A, Diener E. The role of positive and negative emotions in life satisfaction judgment across 
nations. J Pers Soc Psychol 2008; 95: 66-75. 
9. Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients 
at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. 
Lancet 2018; 392: 1036-46. 
10. BBC News. More over-75s should take statins, experts say. 2019. https://www.bbc.co.uk/news/health-47058919 
(accessed 21st October 2019). 
11. Hawkes N. NICE guidelines could put 12 million UK adults on statins. BMJ 2017; 358: j3674. 
12. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with 
elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207. 
13. Newman D. Statin drugs given for five years for heart disease prevention (without known heart disease).  
https://www.bmj.com/content/358/bmj.j3674 
14. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin 
therapy? Curr Atheroscler Rep 2013; 15: 291. 
15. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of 
randomised statin trials. Lancet 2010; 375: 735-42. 
16. Elwood P, Morgan G, White J, et al. Aspirin taking in a south Wales county. Br J Cardiol 2011; 18: 238-40. 
17. Elwood PC, Cochrane AL, Burr ML, et al. A randomized controlled trial of acetyl salicylic acid in the secondary 
prevention of mortality from myocardial infarction. Br Med J 1974; 1: 436-40. 
18. Barbarawi M, Kheiri B, Zayed Y, et al. Aspirin efficacy in primary prevention: a meta-analysis of randomized 
controlled trials. High Blood Press Cardiovasc Prev 2019; 26: 283-91. 
19. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and 
non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 
2012; 379: 1602-12. 
20. Elwood PC, Pickering JE, Morgan G, et al. Systematic review update of observational studies further supports 
aspirin role in cancer treatment: Time to share evidence and decision-making with patients? PLoS One 2018; 13: 
e0203957. 
21. Elwood PC, Morgan G, Galante J, et al. Systematic review and meta-analysis of randomised trials to ascertain 
fatal gastrointestinal bleeding events attributable to preventive low-dose aspirin: no evidence of increased risk. 
PLoS One 2016; 11: e0166166. 
22. Gorelick PB, Weisman SM. Risk of hemorrhagic stroke with aspirin use: an update. Stroke 2005; 36: 1801-7. 
23. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin 
in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. 
HOT Study Group. Lancet 1998; 351: 1755-62. 
24.         Chiuve SE, McCullough ML, Sacks FM, Rimm EB. Healthy lifestyle factors in the primary prevention of coronary 
heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications. 
Circulation 2006;114: 160-167. 
25.        Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women 
through diet and lifestyle. N Engl J Med 2000;343: 16-22. 
26.       Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC. Diet, lifestyle, and the risk of type 
2 diabetes mellitus in women. N Engl J Med 2001;345: 790-797. 
27.        Khaw KT, Wareham N, Bingham S, Welch A, Luben R, Day N. Combined impact of health behaviours and 
mortality in men and women: the EPIC-Norfolk prospective population study. PLoS Med 2008;5: e12. 07-
PLME-RA-1045 [pii];10.1371/journal.pmed.0050012 [doi]. 
8 
 
28.         Kvaavik E, Batty GD, Ursin G, Huxley R, Gale CR (2010) Influence of individual and combined health 
behaviors on total and cause-specific mortality in men and women: the United Kingdom health and lifestyle 
survey. Arch Intern Med 2010; 170: 711-718. 
29.         Protty MB, Wilkins SJ, Hoskins HC, Dawood BB, Hayes J. Prescribing patterns of oral antiplatelets in Wales: 
evolving trends from 2005 to 2016. Future Cardiol 2018; 14: 277-82. 
30. Public Health England. Health profile for England: 2018. 2018. 
https://www.gov.uk/government/publications/health-profile-for-england-2018/chapter-3-trends-in-morbidity-
and-risk-factors (accesse d 21st October 2019). 
31. Diabetes UK. Number of people living with diabetes doubles in twenty years. 2018. 
https://www.diabetes.org.uk/about_us/news/diabetes-prevalence-statistics (accessed 21st October 2019). 
32. NHS England. Dementia. https://www.england.nhs.uk/mental-health/dementia/ (accessed 21st October 2019). 
33. Welsh Government. The Parliamentary Review of Health and Social Care in Wales. 2018. 
https://gov.wales/sites/default/files/publications/2018-01/Review-health-social-care-report-final.pdf (accessed 
21st October 2019). 
 
 
